Quest Diagnostics Q3 2026 Earnings: Volume Growth Drives 10% Revenue Gain

Quest Diagnostics (NYSE: DGX) reported Q3 2026 net revenues of $3.097 billion, up 10.0% from $2.816 billion a year earlier, while GAAP diluted EPS rose 28.7% to $2.78 from $2.16. For the quarter ended September 30, adjusted EPS increased 15.4% to $3.00, as 14.4% organic requisition volume growth more than offset a 4.2% decline in revenue per requisition. Operating cash flow also increased 8.8% to $611 million.

Core Earnings Results

Revenue growth translated into faster GAAP profit growth, with operating income rising 24.2% and net income attributable to Quest Diagnostics increasing 27.6%. Adjusted results showed a more moderate underlying improvement: adjusted operating income grew 13.0%, while adjusted operating margin expanded 40 basis points to 16.7%.

The wider increase in GAAP margin partly reflected more favorable special-item comparisons, while management also cited productivity gains from automation and artificial intelligence.

Adjusted figures exclude items including restructuring and integration costs, amortization, investment gains and losses, and excess tax benefits related to stock-based compensation.

Volume Growth Offset Lower Revenue per Requisition

Diagnostic Information Services revenue reached $3.035 billion, up 10.2% from $2.755 billion. Total requisition volume increased 14.5%, including 14.4% organic growth, while revenue per requisition declined 4.2%.

The figures show that testing volume, rather than higher revenue per test, was the principal revenue driver. Management attributed the volume growth to continued demand across physician, hospital, and consumer channels, supported by the clinical needs of an aging population and increased interest in prevention and wellness. No numerical revenue breakdown by channel was provided.

Cleaner Special-Item Comparisons Amplified GAAP Growth

GAAP operating income increased substantially faster than adjusted operating income, and the GAAP margin expansion of 180 basis points was considerably larger than the 40-basis-point adjusted improvement. The comparison was aided by lower restructuring, integration, and other charges.

Restructuring and integration charges declined to $3 million from $11 million in Q3 2025. Other charges fell to $4 million from $22 million; the prior-year amount included a $15 million charge related to legal matters and a $5 million impairment associated with exiting a business. These differences helped explain why GAAP EPS grew 28.7% while adjusted EPS increased 15.4%.

The adjusted margin increase still indicates underlying operating leverage. Management specifically identified automation and AI-related productivity as contributors, although it did not quantify their individual financial impact.

Cash Flow and Balance Sheet

Quarterly operating cash flow rose to $611 million, while capital expenditures increased 15.0% to $166 million. Based on operating cash flow less capital expenditures, quarterly free cash flow was approximately $445 million, compared with about $419 million in the prior-year quarter.

Cash and cash equivalents increased to $797 million at September 30 from $420 million at the end of 2025. Current and long-term debt totaled approximately $5.55 billion, down from about $5.67 billion at year-end, although long-term debt itself increased as the current portion declined.

For the first nine months of 2026, operating cash flow increased 4.6% to $1.486 billion, while capital expenditures rose 13.2% to $418 million. The faster increase in capital spending limited growth in cash remaining after capital expenditures.

Full-Year 2026 Guidance

Quest Diagnostics raised and narrowed its full-year revenue range and increased both GAAP and adjusted EPS guidance. The operating cash flow outlook also rose by approximately $100 million, while planned capital expenditures remained unchanged.

The adjusted EPS outlook excludes estimated restructuring and integration charges, amortization, contingent consideration changes, investment gains and losses, certain insurance recoveries, and excess tax benefits.

Recent Insider Transactions

The latest disclosed records covering July 22 through September 1, 2026 included three sales, three purchases, two stock grants, one gift, and one derivative-security conversion. These filings describe the transactions but do not by themselves indicate insiders’ views on the company’s valuation or outlook.

Across the broader six-month summary, insiders purchased 43,880 shares and sold 42,424 shares, resulting in net purchases of 1,456 shares, or 0.30% of reported insider holdings.

Risks Investors Need to Watch

• Lower revenue per requisition: Revenue per requisition declined 4.2%, leaving revenue growth dependent on sustained testing-volume gains. A slowdown in volume would reduce the offset to this pressure.
• Cash conversion and receivables: Nine-month operating cash flow grew 4.6%, slower than the 18.4% increase in net income attributable to Quest Diagnostics. Accounts receivable also rose to $1.712 billion from $1.408 billion at year-end.
• Special-item variability: Adjusted EPS excludes several items that can change during the year, including restructuring costs, acquisition-related contingent consideration, investment valuation changes, and stock-compensation tax benefits.
• Debt and capital requirements: Total debt remained approximately $5.55 billion, while the company maintained an annual capital expenditure plan of about $550 million. These commitments affect the cash available for other capital allocation priorities.

Summary

Quest Diagnostics’ Q3 2026 growth was driven primarily by higher testing volume, which outweighed lower revenue per requisition. Underlying profitability improved, while easier special-item comparisons produced faster GAAP earnings growth. Higher operating cash flow and raised full-year revenue and EPS guidance supported the quarter’s overall direction, with revenue per test, cash conversion, and execution against the updated guidance remaining the main areas to monitor.